Novartis Loses Its Case to Stop Sale of Generic Gleevec in India

The Indian manufacturer who sells generic version of Gleevec at approximately $175 a dose, a 15-fold lower price than the drug developer Novaris, will be able to continue to sell it according to the India's Supreme Court. Novartis lost its final appeal of the case....Read Full Post
Source: About.com Biotech Biomedical - Category: Biotechnology Source Type: news